Brief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Wed 20:27
BRIEF-Adial Pharmaceuticals Announces Name Change To Azora Therapeutics Oct 28 (Reuters) - Adial Pharmaceuticals Inc ADIL.O:
ADIAL PHARMACEUTICALS ANNOUNCES NAME CHANGE TO AZORA THERAPEUTICS AND NEW EXECUTIVE TEAM, FOCUSED ON ADVANCING AT177, AN ORAL, COLON-TARGETED AHR AGONIST FOR ULCERATIVE COLITIS
ADIAL PHARMACEUTICALS - CO'S COMMON STOCK TO TRADE AS 'AZR' ON NASDAQ ON OCT 29, 2026
ADIAL PHARMACEUTICALS - APPOINTS MATT DAVIDSON AS PRESIDENT AND CEO EFFECTIVE TODAY
ADIAL PHARMACEUTICALS - APPOINTS CELIA ECONOMIDES AS CHIEF FINANCIAL OFFICER
ADIAL PHARMACEUTICALS - AZORA EXPECTS TO INITIATE PHASE 1 TRIAL OF AT177 IN H1 2027
Source text: ID:nGNX311wc4
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)